Lung Cancer Treatment in Hyderabad
Reviewed May 2026 · Updated August 2026 · Dr. Madhav Danthala
Lung cancer is no longer a smoker's disease. In India, especially in women under 50, more than half of newly diagnosed lung cancers are in people who never smoked. Dr. Madhav Danthala provides treatment planning, chemotherapy, targeted therapy, and immunotherapy at KIMS-Sunshine Hospitals, Begumpet, with evening consultations at Peoples Polyclinic, Manikonda.
When to See a Doctor
Most persistent coughs are not cancer. The pattern that matters is when symptoms are new, persistent, and not explained by infection. Four signs warrant evaluation.
- Persistent cough — more than three weeks, regardless of smoking.
- Blood in sputum — any amount, any episode requires evaluation.
- Unexplained weight loss — more than 5 kg without a change in diet or activity.
- Recurrent infections — pneumonia in the same area twice in a year.
Dr. Danthala's Approach
Lung cancer care today depends as much on molecular testing as on imaging. Three principles shape every consultation.
-
Mutation-led planning
Every adenocarcinoma is profiled for EGFR, ALK, ROS1, KRAS, BRAF, and other actionable mutations before chemotherapy is started, where feasible.
-
More than one path
For locally advanced disease, surgery-first, neoadjuvant chemoradiation, and immunotherapy combinations are all medically defensible. The path is chosen with the patient.
-
Clear, structured communication
Every consult ends with a written summary of options, expected timelines, and the trade-offs each plan carries — so decisions are made calmly, not under pressure.
Treatment Options
Modern lung cancer care is built on a molecular profile, not just a stage. Every adenocarcinoma is tested for actionable mutations before chemotherapy is started where feasible. Below are the major treatment modalities, ordered by how they typically appear in a treatment plan.
Lobectomy or sublobar resection for early-stage NSCLC
For stage I-II non-small-cell lung cancer, surgical resection (typically lobectomy with mediastinal lymph node sampling) offers the best chance of cure. Sublobar resection (segmentectomy or wedge) is acceptable for small peripheral tumours under 2 cm. Video-assisted thoracoscopic surgery (VATS) and robotic approaches reduce recovery time. Adjuvant therapy may follow based on stage and molecular profile.
Osimertinib, alectinib, sotorasib — oral and effective
EGFR mutations (osimertinib), ALK rearrangements (alectinib, brigatinib), ROS1 (entrectinib), KRAS G12C (sotorasib, adagrasib), BRAF V600E, RET, MET, NTRK, and HER2 each have approved oral targeted therapies. These often outperform chemotherapy as first-line therapy and are increasingly being used in the adjuvant setting (osimertinib post-surgery for EGFR+ stage IB-IIIA disease).
PD-1/PD-L1 inhibitors — alone or with chemotherapy
Pembrolizumab, atezolizumab, durvalumab, and nivolumab are now standard for advanced NSCLC without targetable mutations. PD-L1 expression guides whether immunotherapy is given alone or combined with chemotherapy. Durvalumab consolidation after chemoradiation is standard for unresectable stage III disease (PACIFIC regimen). Adjuvant immunotherapy is also increasingly used post-resection.
Platinum doublets, SBRT, concurrent chemoradiation
Platinum-based chemotherapy (cisplatin/carboplatin with pemetrexed or paclitaxel) remains an option in advanced disease without targetable drivers. Stereotactic body radiation therapy (SBRT) is curative-intent for inoperable early-stage NSCLC. Concurrent chemoradiation is the standard for unresectable stage III disease, followed by durvalumab consolidation. Small-cell lung cancer is treated primarily with platinum + etoposide combined with atezolizumab or durvalumab.
Treatment is shaped by stage, molecular profile, performance status, and patient preference. The list above is the menu. The right plan is built with the patient in the room.
From Scan to Systemic Therapy
The most consequential decision in lung cancer is often made before treatment starts: whether to wait for the molecular profile. Two to three weeks of ordered workup decides whether a patient begins on an oral targeted drug, on immunotherapy, or on chemotherapy — three very different lives. This is what that window should contain.
Get enough tissue the first time
Cytology from a pleural tap or a fine-needle aspirate can establish that a cancer exists, but is frequently too little for a full molecular panel. Where the lesion allows, ask for a core biopsy or an EBUS-guided sample taken with sequencing in mind. Repeat procedures cost more time than doing it once properly — and in lung cancer, time spent on the wrong first drug is the expensive kind.
The molecular panel, before the first cycle
Every non-squamous non-small-cell lung cancer should be profiled for EGFR, ALK, ROS1, BRAF V600E, KRAS G12C, MET exon 14 skipping, RET, NTRK and HER2, with PD-L1 by immunohistochemistry alongside. In Indian patients — and especially in non-smokers — EGFR and ALK alterations are common enough that starting platinum chemotherapy before the report returns can mean beginning on the weaker of two available treatments.
Liquid biopsy as a bridge, not a replacement
Plasma circulating-tumour-DNA testing returns faster and can be used when tissue is inadequate or a patient is too unwell to wait. The rule of interpretation is asymmetric: a positive plasma result is actionable; a negative one is not conclusive and still needs tissue confirmation. Used that way, liquid biopsy shortens the wait without lowering the standard.
Staging, brain, and breathing
PET-CT defines the extent of disease. An MRI of the brain belongs in the staging of most newly diagnosed non-small-cell and all small-cell lung cancers, because brain metastases are common and frequently silent — and their presence changes both drug choice and radiation planning. If surgery is being considered, pulmonary function tests and a cardiac assessment decide what the lungs can spare.
The first treatment — chosen, not defaulted
A driver mutation usually means an oral targeted drug first. High PD-L1 without a driver usually means immunotherapy, alone or with chemotherapy. Early-stage disease means surgery or SBRT with adjuvant therapy decided by stage and profile. Small-cell disease moves fastest and starts soonest. The plan should name the reason for its first move, not just its first drug.
Screening changes this whole timeline: a cancer found on a low-dose CT before symptoms is usually a stage-I problem rather than a stage-IV one. Dr. Danthala discusses who should be screened, and why molecular testing replaced one-size-fits-all treatment, on the Cancer Conversations podcast.
Frequently Asked Questions
Can lung cancer happen to people who never smoked?
Yes. In India, especially in women under 50, more than half of newly diagnosed lung cancers are in non-smokers. Causes include air pollution, indoor cooking smoke, occupational exposure, secondhand smoke, and genetic mutations like EGFR which are more common in Asian populations. Tobacco — when it is the driver — also causes oral and laryngeal cancers; the risk profile overlaps and screening conversations should cover both.
When should a persistent cough be evaluated for lung cancer?
Any cough lasting more than three weeks, regardless of smoking history. Immediate concern if there is blood in the sputum, weight loss, breathlessness, or persistent chest pain.
What is EGFR mutation in lung cancer?
EGFR is a gene that, when mutated, drives some lung cancers. EGFR mutations are found in 30 to 40 percent of Asian non-smoker adenocarcinomas. These cancers respond well to targeted oral therapies like osimertinib.
Is low-dose CT screening recommended for lung cancer in India?
For heavy smokers aged 50 to 80 with significant pack-year history, yes. In non-smokers, evidence-based guidelines are still emerging. Discuss imaging with your doctor on an individual basis. Watch the Cancer Conversations World Lung Cancer Day podcast, or see the media page.
What lung cancer treatments are available in Hyderabad?
Surgery for early-stage NSCLC, chemotherapy, targeted therapy (for EGFR, ALK, ROS1, KRAS G12C, etc.), immunotherapy for PD-L1 positive cases, and radiation. Dr. Danthala coordinates care across surgical, medical, and radiation oncology.
Where can I consult Dr. Madhav Danthala for lung cancer treatment in Hyderabad?
Dr. Madhav Danthala consults at KIMS-Sunshine Hospitals, Begumpet (Room 545, 5th Floor OPD, Prakash Nagar 500003; Mon–Sat, 9 AM to 5 PM) and at Peoples Polyclinic, Manikonda (1st Floor, Sree Srinivasam Building 500089; Mon–Sat, 6 PM to 8 PM, prior appointment only). Begumpet appointments are booked online via KIMS Hospitals or KIMS Sunshine. For Manikonda evenings call Naresh on +91 80089 83828, or request a callback.
Can lung cancer be detected before symptoms appear?
Yes — that is what low-dose CT screening is for. By the time a cough, breathlessness or weight loss brings someone in, lung cancer is frequently already advanced; screening is the only reliable way to find it while it is still a small, localised, and often curable problem. Annual low-dose CT is established for long-term smokers and ex-smokers in the eligible age band, and the case for screening some never-smokers in India is under active discussion given how much of the local disease burden is non-smoking. Dr. Madhav Danthala discusses who should be screened on the Cancer Conversations podcast.
How long do lung cancer molecular test results take, and should treatment wait?
A tissue next-generation sequencing panel typically returns in about ten to fourteen days; PD-L1 immunohistochemistry is faster, and plasma circulating-tumour-DNA can return in under a week. In a stable patient, waiting for the panel is usually the right call, because starting platinum chemotherapy in an EGFR- or ALK-driven cancer means beginning on the weaker of two available treatments. If the patient is symptomatic and deteriorating, a liquid biopsy is used to bridge the gap — a positive plasma result is acted on immediately, a negative one still needs tissue.
Is lung cancer curable if caught early?
Yes. Stage I non-small-cell lung cancer treated with surgical resection, or with stereotactic body radiotherapy where surgery is not possible, has a high chance of long-term cure, and adjuvant targeted therapy has further improved outcomes for resected EGFR-mutant disease. The difficulty is not that early lung cancer is untreatable — it is that early lung cancer is usually silent, which is the whole argument for screening rather than waiting for symptoms.
About Dr. Madhav Danthala
Trusted guidelines & further reading
- ESMO — Cancer Guides for Patients European Society for Medical Oncology patient guides — freely accessible, evidence-based.
- ASCO / Cancer.Net — Lung Cancer American Society of Clinical Oncology patient education portal.
- NCI / Cancer.gov — Lung Cancer US National Cancer Institute clinical treatment summaries.
On television & podcast
- Can Lung Cancer Be Detected Before Symptoms? — Cancer Conversations Who needs low-dose CT screening, smoking and vaping risk, and why molecular testing replaced one-size-fits-all treatment. ~19 min.
- Chemotherapy Before Surgery — Neoadjuvant Therapy | Sukhibhava (ETV) Shrinking the tumour before surgery — including in lung cancer — and when organ-sparing becomes possible.
- Cancer Symptoms People Ignore — Vanitha TV The symptoms most often dismissed as infection, and how long is too long to wait.
From our blog
- Lung Cancer in Non-Smokers: India's Quiet Epidemic Why non-smokers — especially Indian women under 50 — are now the most often delayed-to-diagnosis lung cancer patients.
- The Two-Oncologist Rule: When to Get a Second Opinion Lung cancer with a targetable mutation often has multiple defensible treatment paths — second opinions help navigate them.